TLDR:
- Sofinnova Investments appointed Dr. Maha Radhakrishnan as an executive partner, bringing two decades of experience in medical strategy.
- Dr. Radhakrishnan joins from Biogen, where she served as chief medical officer and oversaw FDA-approved products like Aduhelm.
Sofinnova Investments, a venture capital arm based in Menlo Park, California, has named Dr. Maha Radhakrishnan as an executive partner to its investment team. Dr. Radhakrishnan brings extensive experience in global medical strategy and operations from her time at major biotechnology and pharmaceutical companies. She served as chief medical officer at Biogen, where she oversaw the development and approval of products like Aduhelm and Alprolix. Prior to Biogen, she held leadership roles at companies like Sanofi, Bioverativ, and Bristol Myers Squibb.
Dr. Radhakrishnan’s expertise in drug development and commercialization will be invaluable in guiding Sofinnova’s portfolio companies through various stages of development. Sofinnova Investments, known for investing in life science companies, views her appointment as a strategic move to enhance its capabilities in advancing innovative therapies for patients.
In response to her new role, Dr. Radhakrishnan expressed her excitement to leverage her clinical and commercialization experience to drive new investment opportunities within Sofinnova’s portfolio. Her appointment follows the addition of Troy Ignelzi earlier in the year as an executive advisor, further strengthening the team’s financial leadership.
